NASDAQ
20.03.26 | 21:00
11,210 US-Dollar
+0,54 % +0,060
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.02. | Guggenheim raises Phathom stock price target to $25 on revenue beat | 1 | Investing.com | ||
| 26.02. | Phathom outlines $320M-$345M 2026 revenue guidance as company targets operating profitability | 1 | Seeking Alpha | ||
| 26.02. | Stifel reiterates Buy on Phathom stock, keeps $28 price target | 3 | Investing.com | ||
| 26.02. | Phathom Q4 2025 slides: 217% revenue growth, profitability in sight | 3 | Investing.com | ||
| 26.02. | Phathom Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.02. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.01. | Phathom Pharmaceuticals: Stifel bekräftigt "Buy"-Rating nach starkem Umsatzausblick | 7 | Investing.com Deutsch | ||
| 15.01. | Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook | 4 | Investing.com | ||
| 14.01. | Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 | 2 | Investing.com | ||
| 14.01. | Cantor Fitzgerald bestätigt "Overweight" für Phathom und sieht 86 % Kurspotenzial | 6 | Investing.com Deutsch | ||
| 08.01. | Phathom Pharma Shows Sales Strength, Targets 2026 Profitability | 5 | Benzinga.com | ||
| 08.01. | Phathom Pharmaceuticals prices $130 million public offering | 12 | Investing.com | ||
| 08.01. | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals announces public offering of common stock | 3 | Investing.com | ||
| 07.01. | Phathom Pharma plans public offering after reporting preliminary 2025 results | 1 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals kündigt nach Kursrallye öffentliches Aktienangebot an | 5 | Investing.com Deutsch | ||
| 07.01. | Phathom Pharmaceuticals reports Preliminary Q4 results | 2 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | 237 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| 07.01. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 27,835 | -5,16 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| BIOCRYST PHARMACEUTICALS | 8,404 | +0,43 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| IMMUNITYBIO | 7,440 | -2,31 % | ImmunityBio receives Macau approval for bladder cancer drug | ||
| MICROBOT MEDICAL | 2,250 | -0,71 % | Microbot Medical Inc. - 8-K, Current Report | ||
| ATAIBECKLEY | 3,120 | 0,00 % | Milliardenmarkt Depression und PTBS: Wie Emyria und Atai die Psychiatrie-Ökonomie umkrempeln | ||
| CYTOKINETICS | 54,00 | -0,92 % | Mizuho raises Cytokinetics stock price target to $100 on IP extension | ||
| VOYAGER THERAPEUTICS | 3,246 | +0,68 % | Voyager Therapeutics erklärt 2026 zum "Jahr des Tau" | ||
| CAPRICOR | 25,100 | -6,69 % | CAPRICOR THERAPEUTICS, INC. - 10-K, Annual Report | ||
| ARCTURUS THERAPEUTICS | 6,640 | -1,34 % | Cathie Wood's ARK adds 10x Genomics stock, trims Arcturus | ||
| ZEVRA THERAPEUTICS | 8,150 | 0,00 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,040 | +2,02 % | Abeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates | - First ZEVASKYN- commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 - - $191.4M in cash, cash equivalents and short-term investments as... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 14,700 | +3,52 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference | New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,100 | -2,99 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 99,00 | +0,51 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin | Patent strengthens global intellectual property protection for QTORIN rapamycin, Palvella's lead product candidate from the QTORIN platform, in development for serious, rare skin diseases and vascular... ► Artikel lesen | |
| MARKER THERAPEUTICS | 0,990 | -2,94 % | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results | Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,54 % bei einem Aktienkurs von 11,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.